GSK has agreed to acquire Canada’s Bellus Health for around $2 billion, bolting on a late-stage drug candidate for chronic refractory cough. The $14.75-per-share deal will add P2X3 antagonist ...
Zacks Investment Research on MSN6d
TRVI Stock Soars on Meeting Primary Goal in Chronic Cough StudyShares of Trevi Therapeutics TRVI surged 41% yesterday after it reported positive top-line data from the phase IIa RIVER ...
Therapeutic area expertise motivated GSK to acquire Bellus Health and develop a new medicine for patients with refractory chronic cough, which is a disease lacking therapeutic options. GSK’s ...
Last year, GSK also added to its respiratory pipe with an agreement to buy Bellus Health for around $2 billion, adding a P2X3 antagonist, camlipixant, in late-stage development as a chronic cough ...
The most recent such deal happened on Tuesday with GlaxoSmithKline's (GSK) ~$2B acquisition of Canadian Biotech Bellus Health (BLU). The biggest biotech deal so far this year came in March with ...
The drug named camlipixant was added by GSK after it acquired Bellus Health in 2023. GSK expects to launch its RCC drug commercially in 2026. Another company that was once ahead in the RCC drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback